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Abstract
In vitro analysis of inhaled formulations measures, among other parameters, the variability in delivered dose, while
a corresponding in vivo analysis also includes the variability caused by patient performance and distribution of drug
between the oropharynx and the lungs. In vitro, the dose variability is higher for Turbuhaler® than for the
corresponding pMDI, whereas in vivo, the converse is true: the variability in lung deposition is significantly higher,
both between and within subjects, for pMDI than for Turbuhaler. The observation can be due to several factors such
as the non-continuous working principle of inhalation via pMDI as opposed to the continuous working principle of
inhalation via Turbuhaler. © 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
The amount of drug reaching the effector site
determines the elicited effect (Borgstro¨m et al.,
1996; Pauwels et al., 1997). Thus, for inhaled
drugs, it is of interest to evaluate the amount of
drug reaching the lungs. Not only the absolute
value of, but also the variability in, lung deposi-
tion is of interest, as a large variability in lung
deposition could be reflected in the exerted effects.
The overall delivery of inhaled drugs to the effec-
tor site can be described by a number of steps:
dose metering, aerosol generation, dose delivery
(from inhaler to patient), partition of delivered
dose between oropharynx and lungs, and, finally,
regional deposition of drug reaching the lung.
Variability in the different steps will add up to an
overall variability in the amount of drug reaching
the lungs. The variability in lung deposition thus
depends on a large number of in vitro and in vivo
factors, e.g. device performance, handling of the
device, co-ordination of actuation and inhalation,
inhalation flow, patient anatomy etc. In vitro
analysis is done to ascertain a good quality of the
manufactured product and the analyses are done
under strictly standardised conditions. The abso-* Corresponding author.
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lute amount of drug leaving the inhaler and its
variability are typical in vitro parameters. The in
vivo analysis includes lung deposition and its
variability, but also the clinical outcome of the
dose reaching the lungs. The measured in vitro
variability thus is only a small portion of the
overall in vivo variability observed in the clinical
situation.
Lung deposition of inhaled drug can be mea-
sured with different methods, gamma-scintigraphy
and pharmacokinetic methods being the most
widely used (Borgstro¨m and Nilsson, 1990; New-
man et al., 1995; Pauwels et al., 1997). In the
present study the pharmacokinetic charcoal-block
method was used. The method takes advantage of
the fact that if the uptake of the oral and gas-
trointestinal portion of an inhaled drug is blocked
by activated charcoal, then the amount of active
drug reaching the systemic circulation equals the
amount of active drug absorbed over the lung
membrane. This amount equals the lung deposi-
tion. Pharmacokinetic methods are based on mea-
surements of plasma and urine concentrations and
thus the variability in the bioanalytical method
adds to the overall variability. This methodologi-
cal variability is probably of minor importance
compared with variability in the other factors
discussed above. A previous study investigated the
variability in lung deposition in healthy volunteers
(Beckman et al., 1996). From that study it was
concluded that both variability between subjects
(intervariability) and variability within subjects
(intravariability) in lung deposition were lower for
the dry powder inhaler, DPI, Turbuhaler than for
a pressurised metered dose inhaler, pMDI.
The aim of the present investigation was to
determine the intra-, and intervariability in lung
deposition in asthmatic patients when they in-
haled terbutaline sulphate (Bricanyl®) via two dif-
ferent kinds of inhalers, a pMDI and a DPI,
Turbuhaler. The results from the previous study
in healthy volunteers are given for reference. The
present investigation was part of a more extensive
study. The main aim of this study was to investi-
gate if differences in the amount of terbutaline
sulphate reaching the lungs were reflected in a
difference in protective effect against a metha-
choline or a histamine provocation.
2. Material and methods
Thirteen asthmatic patients (nine men) were
included in the study. Their mean age was 28
years (range 19–48) and their mean FEV1 was 3.4
L (2.6–4.6), corresponding to 85% of predicted, at
inclusion. Patients were asked to inhale terbuta-
line sulphate (Bricanyl®) from a pMDI or Tur-
buhaler at nominal doses of 0.25 or 0.5 mg and its
protective effect against methacholine or his-
tamine provocation was tested. The study was
double-blind, crossover and randomised with re-
spect to the provocative agent. The amount of
drug reaching the lungs, lung deposition, was
calculated at each inhalation, with the aid of a
pharmacokinetic method (Borgstro¨m and Nilsson,
1990). The 0.5 mg dose was given as two doses of
0.25 mg. Thus, the measured lung deposition val-
ues, in percentage of dose, for the 0.5 mg doses is
the mean of two 0.25 mg doses. For each patient
eight determinations of lung deposition were gen-
erated, making it possible to calculate the intra-,
as well as the intervariability in lung deposition of
the inhaled drug. The results from the lung depo-
sition versus effect part of the study have been
reported elsewhere (Derom et al., 1999). Lung
deposition was compared between devices using a
multiplicative ANOVA model with factors pa-
tient, visit, device, dose and interaction device by
dose. A multiplicative model means that data
were analysed on a logarithmic scale. The intra-
and intervariability in lung deposition with each
device was assessed using a linear mixed effects
model (LINMEM) accounting for device and visit
as fixed factors. Differences in the doses within
the same device for asthmatic patients were as-
sumed to be part of the variability. The estimated
variances on the logarithmic scale were expressed
as coefficients of variation (CV) on the linear
scale.
3. Results
The absolute amount of drug reaching the
lungs differed significantly between the two in-
halers (Table 1). The value given for the ratio of
Turbuhaler:pMDI is the ratio between the mean
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Table 1
Lung deposition (percentage of nominal metered dose) after inhalation of terbutaline sulphate via pMDI or Turbuhaler in the
asthmatic patients group
Treatment 95% conf. lim. (%)Lung deposition (%) Range (%)
20.8Turbuhaler 0.25 mg 16.4–26.6 9.7–54.1
13.2–21.716.9 7.3–50.7Turbuhaler 0.5 mg
3.8–6.1 0.2–15.9pMDI 0.25 mg 4.8
5.8–9.5 1.1–53.77.4pMDI 0.5 mg
2.46–4.01Turbuhaler:pMDI ratio 3.14
deposition for Turbuhaler and pMDI, respec-
tively.
The absolute values for Turbuhaler were about
three times higher than the pMDI values. This is
at accord with a previous study where similar
values were observed (Borgstro¨m et al., 1996).
The values obtained for inter- and intravariabil-
ity are given in Table 2.
4. Discussion
The intra- and interindividual variability in
lung deposition for pMDI and Turbuhaler was
previously assessed in 12 healthy subjects in an
open, crossover and randomised study (Beckman
et al., 1996). A re-calculation of the variability
from that study with the LINMEM technique,
giving more consistent estimates of the influence
of the intravariability on the intervariability, are
given together with the results from the present
study in Table 2. In the previous study the Tur-
buhaler and pMDI inhalers were also analysed in
vitro. Intra-device variability expressed as CV,
was 6.4% for pMDI and 18.2% for Turbuhaler, a
significant (PB0.001) difference. Also the inter-
device variability was significantly higher for Tur-
buhaler than for pMDI; the ratio of CVs was 2.0
(P0.023).
It should be observed that in vitro analyses are
not primarily designed to predict the in vivo
behaviour of a tested formulation. The in vitro
analyses are designed to judge if an individual
batch of the pharmaceutical formulation complies
with the approved specifications. The in vitro
analyses can be regarded as a final evaluation of
all the steps in the manufacturing process. Thus,
one should not expect the in vitro behaviour of an
inhaled formulation to be a predictor of its in vivo
behaviour unless this has been shown to be the
case for a specific set of in vitro:in vivo parame-
ters. This is the case for the relation between fine
particle dose (FPD) and lung deposition. It has
been shown that FPD, measured with an in vivo
like inlet on the impactor, can be used to predict
the lung deposition for different DPIs and pMDIs
(Olsson et al., 1996).
In the present study, the intravariability in lung
deposition in patients was similar for the two
devices, while for the healthy subjects it was
higher for the pMDI. Taken together this con-
firms that factors other than the generation of the
inhaled aerosol are of importance for the overall
variability seen in lung deposition. It also suggests
that day to day variability, if anything, is lower
for the DPI than for the corresponding pMDI.
The resulting lung dose is probably only to a
small degree dependent on the variability in the
properties of the generated aerosol cloud, and is
Table 2
Inter- and intravariability in lung deposition of terbutaline
inhaled via pMDI or Turbuhalera
PatientsDevice Healthy volunteers
Inter IntraIntraInter
Turbuhaler 8.17 39.3 18.5 47.1
61.2 39.1PMDI 73.046.7
a Values are expressed as coefficients of variation (%). Val-
ues for healthy volunteers are given for comparison and are
re-calculated from reference (Beckman et al., 1996)
L. Borgstro¨m et al. : International Journal of Pharmaceutics 193 (2000) 227–230230
more dependent on the interaction between the
aerosol cloud and the oral cavity of the inhaling
subject.
The observed difference in intervariability, be-
tween pMDI and Turbuhaler, seen both in pa-
tients and healthy volunteers, indicates that the
performance of Turbuhaler is more subject inde-
pendent than the corresponding pMDI. In the
case of a patient, the lung deposition is more
predictable when prescribing Turbuhaler than
when prescribing the corresponding pMDI. The
observed difference in variability in lung deposi-
tion between the DPI Turbuhaler and the pMDI
probably represents a class difference between
breath actuated DPIs and pMDIs. This is because
the generation of aerosol and inhalation is a
continuous process with breath actuated DPIs in
contrast to pMDIs where aerosol generation and
inhalation of the generated aerosol are two dis-
tinct processes that need to be co-ordinated by the
inhaling subject. This difference can explain the
results obtained.
Collectively, we have shown that in an asth-
matic patient population the inhalation of terbu-
taline sulphate from Turbuhaler gives a more
reproducible dose to the effector organ, the lungs,
than inhalation of an equivalent dose from the
corresponding pMDI.
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